Iceland· IS-EU/1/97/053/003-005
Cerezyme
A imiglucerase product containing imiglucerasum inn, registered in Iceland by Sanofi B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Imiglucerase is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB02 (imiglucerase), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Imiglucerase · ATC A16AB02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Imiglucerasum INN
- Manufacturer
- Sanofi B.V.
- Country
- Iceland (IS)
- ATC code
- A16AB02
- ATC class
- Imiglucerase
- Defined daily dose
- 300 E, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1 interaction on record for imiglucerase.
Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Imiglucerase · interactions on record
1 record
- 1 moderate
Most severe, free to view
- MiglustatA16AX06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Imiglucerase in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandCerezymeOrifarm Oy
- CzechiaCEREZYMESanofi B.V., Amsterdam
- IrelandCerezyme 400 Units Powder for concentrate for solution for infusionSanofi B.V.
- United StatesCerezymeGenzyme Corporation
- United KingdomCerezyme 200unit powder for solution for infusion vialsGenzyme Therapeutics Ltd
- BelgiumCerezyme 200 USanofi
- FranceCEREZYME 400 U, poudre pour solution à diluer pour perfusionSANOFI (PAYS-BAS)
- PolandCerezymeSanofi B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Cerezyme
- Norway · Cerezyme
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bdc00064-213b-44e1-a34a-1094cfb6fffc GET /v1/drugs/bdc00064-213b-44e1-a34a-1094cfb6fffc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stofn fyrir innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "A16AB02",
"marketed": false,
"strength": "400 ein.",
"ma_number": "EU/1/97/053/003-005",
"substance": "Imiglucerasum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "37662"
}See everything about imiglucerase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.